Evidence map›Paper›PMID 38363477›Full record

ArticleJournal of clinical immunology2024

A Novel Heterozygous Variant in AICDA Impairs Ig Class Switching and Somatic Hypermutation in Human B Cells and is Associated with Autosomal Dominant HIGM2 Syndrome.

Erika Della Mina, Katherine J L Jackson, Alexander J I Crawford, Megan L Faulks, Karrnan Pathmanandavel, Nicolino Acquarola, Michael O'Sullivan, Tessa Kerre, Leslie Naesens, Karlien Claes and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of clinical immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 3 countries.

Erika Della MinaGarvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.
Katherine J L JacksonGarvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.
Alexander J I CrawfordGarvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.
Megan L FaulksGarvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.
Karrnan PathmanandavelGarvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.
Nicolino AcquarolaDepartment of Clinical Immunology and PathWest, Fiona Stanley Hospital, Murdoch, WA, Australia.
Michael O'SullivanDepartment of Clinical Immunology and PathWest, Fiona Stanley Hospital, Murdoch, WA, Australia.
Tessa KerreDepartment of Hematology, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
Leslie NaesensCenter for Primary Immunodeficiency Ghent (CPIG), Jeffrey Modell Diagnosis and Research Center, ERN Rita Network Center, Ghent University Hospital, Ghent, Belgium.
Karlien ClaesCenter for Primary Immunodeficiency Ghent (CPIG), Jeffrey Modell Diagnosis and Research Center, ERN Rita Network Center, Ghent University Hospital, Ghent, Belgium.
Christopher C GoodnowGarvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.
Filomeen HaerynckCenter for Primary Immunodeficiency Ghent (CPIG), Jeffrey Modell Diagnosis and Research Center, ERN Rita Network Center, Ghent University Hospital, Ghent, Belgium.
Sven KrackerLaboratory of Human Lymphohematopoiesis, INSERM UMR 1163, Imagine Institute, 75015, Paris, France.
Isabelle MeytsInborn Errors of Immunity, Department of Microbiology, Immunology and Transplantation, KU Leuven, Louvain, Belgium.
Lloyd J D'Orsogna *Department of Clinical Immunology and PathWest, Fiona Stanley Hospital, Murdoch, WA, Australia.
Cindy S Ma *Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.
Stuart G TangyeGarvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia. s.tangye@garvan.org.au.ORCID 0000-0002-5360-5180
Garvan Institute of Medical Research · AUGhent University Hospital · BEFiona Stanley Hospital · AUInserm · FRKU Leuven · BEPrincess Margaret Hospital for Children · AUThe University of Western Australia · AU

Funding

National Health and Medical Research Council 1042925National Health and Medical Research Council 1113904National Health and Medical Research Council 2017463
6 · The paper itself

Abstract

B cells and their secreted antibodies are fundamental for host-defense against pathogens. The generation of high-affinity class switched antibodies results from both somatic hypermutation (SHM) of the immunoglobulin (Ig) variable region genes of the B-cell receptor and class switch recombination (CSR) which alters the Ig heavy chain constant region. Both of these processes are initiated by the enzyme activation-induced cytidine deaminase (AID), encoded by AICDA. Deleterious variants in AICDA are causal of hyper-IgM syndrome type 2 (HIGM2), a B-cell intrinsic primary immunodeficiency characterised by recurrent infections and low serum IgG and IgA levels. Biallelic variants affecting exons 2, 3 or 4 of AICDA have been identified that impair both CSR and SHM in patients with autosomal recessive HIGM2. Interestingly, B cells from patients with autosomal dominant HIGM2, caused by heterozygous variants (V186X, R190X) located in AICDA exon 5 encoding the nuclear export signal (NES) domain, show abolished CSR but variable SHM. We herein report the immunological and functional phenotype of two related patients presenting with common variable immunodeficiency who were found to have a novel heterozygous variant in AICDA (L189X). This variant led to a truncated AID protein lacking the last 10 amino acids of the NES at the C-terminal domain. Interestingly, patients' B cells carrying the L189X variant exhibited not only greatly impaired CSR but also SHM in vivo, as well as CSR and production of IgG and IgA in vitro. Our findings demonstrate that the NES domain of AID can be essential for SHM, as well as for CSR, thereby refining the correlation between AICDA genotype and SHM phenotype as well as broadening our understanding of the pathophysiology of HIGM disorders.

Indexed as

Cytidine DeaminaseHyper-IgM Immunodeficiency SyndromeImmunoglobulin Class SwitchingAICDA (Activation-Induced Cytidine Deaminase)HumansImmunoglobulin AImmunoglobulin GPhenotypeSomatic Hypermutation, ImmunoglobulinAICDA (Activation-Induced Cytidine Deaminase)Cytidine DeaminaseImmunoglobulin AImmunoglobulin GAICDAHIGM2Human B cellsIg class switchingSomatic hypermutation

Identifiers

PMID38363477
PMCPMC10873450
OpenAlexW4391883111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.